CR11341A - Combinacion que comprende derivados de purina y otros compuestos y el uso de los mismos para el tratamiento de enfermedades de vias respiratorias inflamatorias y obstructivas - Google Patents
Combinacion que comprende derivados de purina y otros compuestos y el uso de los mismos para el tratamiento de enfermedades de vias respiratorias inflamatorias y obstructivasInfo
- Publication number
- CR11341A CR11341A CR11341A CR11341A CR11341A CR 11341 A CR11341 A CR 11341A CR 11341 A CR11341 A CR 11341A CR 11341 A CR11341 A CR 11341A CR 11341 A CR11341 A CR 11341A
- Authority
- CR
- Costa Rica
- Prior art keywords
- inflammatory
- antagonist
- treatment
- inhibitor
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000002757 inflammatory effect Effects 0.000 title abstract 2
- 230000000414 obstructive effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 title 1
- 150000003212 purines Chemical class 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 239000005557 antagonist Substances 0.000 abstract 4
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 abstract 2
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 abstract 2
- 229940122614 Adenosine receptor agonist Drugs 0.000 abstract 1
- 101150051188 Adora2a gene Proteins 0.000 abstract 1
- 229940123169 Caspase inhibitor Drugs 0.000 abstract 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 abstract 1
- 229940126052 ENaC inhibitor Drugs 0.000 abstract 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 abstract 1
- 229940122055 Serine protease inhibitor Drugs 0.000 abstract 1
- 101710102218 Serine protease inhibitor Proteins 0.000 abstract 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 abstract 1
- 239000000048 adrenergic agonist Substances 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000001387 anti-histamine Effects 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000002713 epithelial sodium channel blocking agent Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 abstract 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 abstract 1
- 239000003149 muscarinic antagonist Substances 0.000 abstract 1
- 230000003551 muscarinic effect Effects 0.000 abstract 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 239000003001 serine protease inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Un medicamento que comprende, por separado o juntos: un componente (A) el cual es un agonista de receptor de adenosina A2A como se define en la especificacion; y un componente (B) el cual es uno o mas compuestos seleccionados de: (i) un corticosteroide, (ii) un agonista de beta-2 adrenoceptor, (iii) un agente antimuscarinico, (iv) un antagonista de A2B, (v) una antihistamina, (Vi) un inhibidor de caspasa, (vii) un inhibidor de ENaC, (viii) un antagonista de LTB4, (ix) un antagonista de LTD4, (x) un inhibidor de serina proteasa, (xi) un inhibidor de PDE4 y (xii) un agonista de beta-2 adrenoceptor / antagonista muscarinico de accion dual, para administracion simultanea, secuencial o separada en el tratamiento de una enfermedad inflamatoria u obstructiva de vias respiratorias.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07118721 | 2007-10-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR11341A true CR11341A (es) | 2010-05-06 |
Family
ID=39185790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR11341A CR11341A (es) | 2007-10-17 | 2010-03-26 | Combinacion que comprende derivados de purina y otros compuestos y el uso de los mismos para el tratamiento de enfermedades de vias respiratorias inflamatorias y obstructivas |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20090181934A1 (es) |
| EP (1) | EP2211865A2 (es) |
| JP (1) | JP2011500630A (es) |
| KR (1) | KR20100075925A (es) |
| CN (1) | CN101827596A (es) |
| AR (1) | AR068879A1 (es) |
| AU (1) | AU2008313788A1 (es) |
| BR (1) | BRPI0818005A2 (es) |
| CA (1) | CA2702942A1 (es) |
| CL (1) | CL2008003057A1 (es) |
| CR (1) | CR11341A (es) |
| CU (1) | CU20100065A7 (es) |
| EA (1) | EA201000617A1 (es) |
| IL (1) | IL204723A0 (es) |
| MA (1) | MA31796B1 (es) |
| MX (1) | MX2010004252A (es) |
| PE (1) | PE20091392A1 (es) |
| TN (1) | TN2010000168A1 (es) |
| TW (1) | TW200927129A (es) |
| WO (1) | WO2009050198A2 (es) |
| ZA (1) | ZA201002336B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0500785D0 (en) | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| GB0607944D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607945D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| PE20080361A1 (es) | 2006-04-21 | 2008-06-03 | Novartis Ag | Compuestos derivados de purina como activadores del receptor de adenosina a2a |
| GB0607950D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607948D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607953D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| EP1889846A1 (en) | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
| EP1903044A1 (en) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
| WO2008055874A1 (en) * | 2006-11-10 | 2008-05-15 | Novartis Ag | Cyclopentene diol monoacetate derivatives |
| WO2009050199A1 (en) * | 2007-10-17 | 2009-04-23 | Novartis Ag | Purine derivatives as adenosine al receptor ligands |
| AU2013251079B2 (en) | 2012-04-20 | 2017-03-23 | Ucb Pharma S.A. | Methods for treating Parkinson's disease |
| JOP20210164A1 (ar) | 2019-01-11 | 2023-01-30 | Omeros Corp | طرق وتركيبات علاج السرطان |
| WO2026006723A1 (en) * | 2024-06-27 | 2026-01-02 | Anand Rene | Reagents and methods for treating headache and migraine pain and co-morbidities thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| PE20080361A1 (es) * | 2006-04-21 | 2008-06-03 | Novartis Ag | Compuestos derivados de purina como activadores del receptor de adenosina a2a |
| GB0607953D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607950D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607945D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
-
2008
- 2008-10-08 US US12/247,764 patent/US20090181934A1/en not_active Abandoned
- 2008-10-15 PE PE2008001774A patent/PE20091392A1/es not_active Application Discontinuation
- 2008-10-15 AR ARP080104494A patent/AR068879A1/es not_active Application Discontinuation
- 2008-10-15 EP EP08838649A patent/EP2211865A2/en not_active Withdrawn
- 2008-10-15 MX MX2010004252A patent/MX2010004252A/es not_active Application Discontinuation
- 2008-10-15 BR BRPI0818005 patent/BRPI0818005A2/pt not_active IP Right Cessation
- 2008-10-15 WO PCT/EP2008/063869 patent/WO2009050198A2/en not_active Ceased
- 2008-10-15 EA EA201000617A patent/EA201000617A1/ru unknown
- 2008-10-15 CN CN200880112188A patent/CN101827596A/zh active Pending
- 2008-10-15 KR KR1020107008300A patent/KR20100075925A/ko not_active Withdrawn
- 2008-10-15 CA CA2702942A patent/CA2702942A1/en not_active Abandoned
- 2008-10-15 AU AU2008313788A patent/AU2008313788A1/en not_active Abandoned
- 2008-10-15 JP JP2010529369A patent/JP2011500630A/ja active Pending
- 2008-10-16 TW TW097139728A patent/TW200927129A/zh unknown
- 2008-10-16 CL CL2008003057A patent/CL2008003057A1/es unknown
-
2010
- 2010-03-25 IL IL204723A patent/IL204723A0/en unknown
- 2010-03-26 CR CR11341A patent/CR11341A/es not_active Application Discontinuation
- 2010-04-01 ZA ZA2010/02336A patent/ZA201002336B/en unknown
- 2010-04-14 CU CU20100065A patent/CU20100065A7/es unknown
- 2010-04-16 TN TN2010000168A patent/TN2010000168A1/fr unknown
- 2010-04-30 MA MA32802A patent/MA31796B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20091392A1 (es) | 2009-10-14 |
| WO2009050198A2 (en) | 2009-04-23 |
| JP2011500630A (ja) | 2011-01-06 |
| ZA201002336B (en) | 2011-04-28 |
| MX2010004252A (es) | 2010-04-30 |
| MA31796B1 (fr) | 2010-10-01 |
| BRPI0818005A2 (pt) | 2015-04-14 |
| CU20100065A7 (es) | 2011-10-05 |
| AU2008313788A1 (en) | 2009-04-23 |
| EP2211865A2 (en) | 2010-08-04 |
| EA201000617A1 (ru) | 2010-10-29 |
| US20090181934A1 (en) | 2009-07-16 |
| AR068879A1 (es) | 2009-12-09 |
| CL2008003057A1 (es) | 2009-06-26 |
| KR20100075925A (ko) | 2010-07-05 |
| TW200927129A (en) | 2009-07-01 |
| IL204723A0 (en) | 2010-11-30 |
| CN101827596A (zh) | 2010-09-08 |
| WO2009050198A3 (en) | 2009-09-11 |
| TN2010000168A1 (en) | 2011-11-11 |
| CA2702942A1 (en) | 2009-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR11341A (es) | Combinacion que comprende derivados de purina y otros compuestos y el uso de los mismos para el tratamiento de enfermedades de vias respiratorias inflamatorias y obstructivas | |
| GT200800219A (es) | Derivados de purina para utilizarse como agonistas del receptor de adenosina a2a | |
| CO6390066A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| JP7083497B2 (ja) | がんの処置のための併用療法 | |
| ECSP109935A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
| CU20090103A7 (es) | Derivados de 2,3-dihidroimidazol[1,2-c]quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis | |
| UY30559A1 (es) | Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
| ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| MX347525B (es) | Inhibidores de tirosina cinasa de bruton. | |
| CL2013001136A1 (es) | Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional. | |
| WO2009017838A3 (en) | Combinations of jak-2 inhibitors and other agents | |
| CL2007003289A1 (es) | Compuestos derivados de biciclocarboxiamida; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades provocadas por la hiperactivacion del receptor vc1 como dolor, enfermedad de vejiga, inflam | |
| AR051968A1 (es) | Metodos y composiciones que utilizan inhibidores de jnk para el tratamiento y manejo de la lesion del sistema nervioso central | |
| GT200900089A (es) | Composicion farmaceutica en forma de microesferas recubiertas para la liberacion modificada de un relajante muscular y un aine | |
| AR055123A1 (es) | Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta, composicion farmaceutica que la contiene y su aplicacin en terapeutica | |
| MX2021005839A (es) | Antagonistas del receptor de adenosina aminotriazolopirimidina y aminotriazolopirazina sustituidos, composiciones farmaceuticas y su uso. | |
| DK1959939T3 (da) | Anvendelse af a3-adenosinreceptoragonist i behandlingen af osteoarthritis | |
| AR049262A1 (es) | Combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias | |
| AR060284A1 (es) | Terapia de combinacion de (2r,z)-2-amino-2-ciclohexil-n-(5-(1-metil-1h- pirazol- 4-il)-1- oxo- 2,6 dihidro-1h- [1,2] diazepino [4,5,6-cd] indol-8-il) acetamida | |
| MX2013001279A (es) | Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral. | |
| UY30424A1 (es) | Derivados de quinolina, su preparacion, su uso y medicamentos que comprenden los mismos. | |
| AR049136A1 (es) | Composicion y metodo con irinotecan (cpt-11) y un inhibidor del egfr,como erlotinib | |
| MX2010004090A (es) | Uso de norgestimato como un inhibidor selectivo de los canales ionicos trpc3, trpc6 y trpc7. | |
| AR073086A1 (es) | Composicion farmaceutica para el tratamiento de un trastorno de ansiedad que comprende exo-7-(8-h-8-aza-biciclo(3,2,1)oct-3-iloxi)-cromen-2-ona, uso y equipo | |
| PY0228254A (es) | Combinacion farmaceutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |